Nivalis Therapeutics, Inc. (ALPN)

Last Three Months

14-Feb-24 -- 13-May-24

Time Period:

Three Months
|
Year

0 Net Amount

Buy:	0	--
Sell:	0	--

Company Sentiment

Biotechnology

Drugs

Insider Trading Sentiment: Buy

Insider Trading Sentiment: Strong Buy

Sentiment Breakdown by Insider

0

(3)

0

(2)

0

(1)

23

0

5

+1

0

+2

0

+3

Two Year Chart

14-May-22 -- 13-May-24

Price ($)

Two Year Stock Price Chart

Sentiment

Buy & Sell Volume ($)

Two Year Insider Trading Volume Chart

Recent Insider Trades

Last Transaction		Last Three Months
SEC Filing	Transaction	Insider	Sentiment	Company	Holdings Change	Buy Amount	Sell Amount	Buy Price Range	Sell Price Range
10-May-24 7:26 PM View:	08-May-24 Option Exercise $669.40K	Peng Stanford L See Remarks		Nivalis Therapeutics, Inc. - ALPN	376% 72.37K to 344.16K	0	0	--	--	Show Txns Hide Txns

29-Apr-24 4:32 PM View:	25-Apr-24 Sale ($1.23K)	Topper James N Director		Nivalis Therapeutics, Inc. - ALPN	74% 1.63M to 2.83M	0	0	--	--	Show Txns Hide Txns

09-May-24 9:13 PM View:	07-May-24 Option Exercise $161.63K	Rickey James Paul See Remarks		Nivalis Therapeutics, Inc. - ALPN	86% 31.2K to 57.96K	0	0	--	--	Show Txns Hide Txns

10-May-24 7:24 PM View:	08-May-24 Option Exercise $100.00K	Gold Mitchell Executive Chairman and CEO Director		Nivalis Therapeutics, Inc. - ALPN	0% 2.72M to 2.74M	0	0	--	--	Show Txns Hide Txns

10-May-24 7:25 PM View:	08-May-24 Option Exercise $513.87K	Durand Remy Chief Business Officer		Nivalis Therapeutics, Inc. - ALPN	250% 38.1K to 133.39K	0	0	--	--	Show Txns Hide Txns

10-May-24 7:22 PM View:	08-May-24 Option Exercise $275.44K	Fuhs Ulrich Martin Chief Accounting Officer		Nivalis Therapeutics, Inc. - ALPN	313% 7.3K to 30.12K	0	0	--	--	Show Txns Hide Txns